ArticleHuman vaccines & immunotherapeutics2026
Dynamic epidemiological changes of hand, foot, and mouth disease and real-world effectiveness of EV-A71 vaccination: A case study in Shanghai (2009-2023).
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A significant reduction in hand-foot-mouth disease (HFMD) cases has occurred across the country, since EV-A71 vaccine was licensed for use in China in 2016. We compared the epidemiology and virological characteristics before and after the implementation of EV-A71 vaccination over a 15-y period in Minhang district, Shanghai, and conducted a test-negative design to estimate the vaccine effectiveness (VE) of EV-A71 vaccine against HFMD. A total of 73,160 HFMD cases, 361 severe cases, and 3 fatalities were reported in the Minhang district, Shanghai during 2009-2023. After the implementation of EV-A71 vaccine program, the incidence rate, case-severity rate, and fatality rate of HFMD showed a significant decline by 56.7%, 95.2%, and 100.0%, respectively. The proportion of age group 6-10 y increased by 105.7%. The predominance of EV-A71 and CV-A16 was replaced by CV-A6 and CV-A10 in the post-2017 period. Full-dose immunization coverage rate maintained 50% during 2019-2023. The overall VE against EV-A71-associated HFMD and herpangina was 89.9% (95% CI: 74.5-96.0) for two-dose series and 67.9% (95% CI: 2.6-89.6) for one-dose vaccination. The VE for two-dose vaccination was 92.2%, 88.1%, and 100% against EV-A71-associated outpatient visit, non-severe hospitalization, and severe complications, respectively. There was no cross-protective effect of EV-A71 vaccination against non-EV-A71 serotype infection. EV-A71 vaccination program substantially reduced HFMD burden in Shanghai, with two-dose series providing robust protection against EV-A71-associated HFMD and herpangina. The shift of non-EV-A71 serotypes warrants an effort to develop multivalent vaccines to control HFMD epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.